HIGH QUALITY SCIENTIFIC CONTENT,  ONLINE OPEN ACCESS,  GLOBAL SCIENTIFIC AUDIENCE,  COST EFFECTIVE, ANY ONE CAN DOWNLOAD REPRINTS 
Spreading knowledge

Google Scholar

Google Scholar

Archives

Back 

REVIEW ON RECENT ADVANCES IN CHEMOTHERAPY OF TUBERCULOSIS. Ashish Kaushal, Ruchika Ohri, Chander Mohan

REVIEW ON RECENT ADVANCES IN CHEMOTHERAPY OF TUBERCULOSIS.

Ashish Kaushal, Ruchika Ohri, Chander Mohan

International Journal of Natural Product Science 2012: Spl Issue 1:217.

Abstract(RBIP-217)

Tuberculosis (TB) is an infectious disease, caused by several species of mycobacterium. The important human pathogens of this class are Mycobacterium tuberculosis and Mycobacterium bovis. During the 16 years since the World Health Organization declared tuberculosis (TB) a global emergency, major new challenges have emerged in particular the spread of extensively drug-resistant (XDR)-TB and its overlap with human immunodeficiency virus infection. WHO has instituted a Global TB Control Programme based on the directly observed treatment short course (DOTS) strategy. Much of the principles of this strategy have come out of research in India. As part of this strategy, the Government of India is implementing a Revised National Tuberculosis Control Programme (RNTCP). Under the RNTCP standardized treatment regimens are prescribed for different treatment categories. Already more than 80percent of the population is covered by this Programme and full coverage is slated for 2005. Although treatment of drug-susceptible tuberculosis (TB) under ideal conditions may be successful in 95% of cases, cure rates in the field are often significantly lower due to the logistical challenges of administering and properly supervising the intake of combination chemotherapy for 6–9 months. DOTS is a proven cost-effective TB treatment strategy. A combination of technical and managerial components, DOTS quickly makes infectious cases non-infectious and breaks the cycle of transmission. Using DOTS also prevents the development of drug-resistant strains of TB that are often fatal and very expensive to cure. The current global concern in the treatment of tuberculosis (TB) is the emergence of resistance to the two most potent drugs viz., isoniazid and rifampicin.
Attachments:
Time to create page: 0.13 seconds


Copyright © All rights reserved Science Instinct Publications sciipub.com